New method of bacterial cell engineering can produce better, cheaper drug therapies
Therapeutic proteins, which provide cutting-edge treatments of cancer, diabetes and countless other diseases, are among today's most widely consumed biopharmaceuticals. By introducing bottom-up carbohydrate engineering into common bacterial cells, Cornell researchers have discovered a way to make these drugs cheaper and safer.
A research team led by Matthew DeLisa, associate professor of chemical and biomolecular engineering, has invented a novel method for engineering human therapeutic glycoproteins simply and quickly using E. coli bacteria as a platform. Their work is detailed online March 25 in Nature Chemical Biology.
read more: http://www.news.cornell.edu/stories/March12/delisaGlyco.html